Skip to main content
Sign In

University of Colorado Denver Hematology, Blood Cancer, Bone Marrow Transplant Program

 Blood Cancer, Bone Marrow Transplant Program Logo
 

Clinical Trials

​See what human subject trials are accepting applicants


For more information click the study identifier or search the identifier number at clinicaltrials.gov.

 Mastocytosis

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NC​T02561988​
A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Ryan Scannura​, 720-848-8033
12

 Non Hodgkin Lymphoma

​ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
​​NCT02567656 ​​A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma ​Kelsey Moore, 720-848-8089​​​
NCT02443077 ​​​A randomized, double-blind, phase 3 study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with replapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype ​Tricia Feddick, 720-848-8034
NCT02580552 ​A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type ​Bradley Haverkos​
NCT02448381 ​A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma ​Bradley Haverkos​
NCT02568267 ​An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements ​Bradley Haverkos​
NCT02731742 ​A Phase 1/1b Trial of MK-1966 (mAb against IL-10) in Combination with SD-101 (TLR9 agonist) in Subjects With Advanced Malignancies ​Bradley Haverkos​
NCT02327078 ​A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat (IDO inhibitor) Administered in Combination With Nivolumab in Select Advanced Cancers (including DLBCL) ​Bradley Haverkos​
NCT02635672 ​An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 (CDK9 inhibitor) in Patients With Advanced Hematological Malignancies (including NHL and CMYC+ NHL) ​Bradley Haverkos​
NCT02702492 ​A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin Lymphoma​ ​​Bradley Haverkos​
NCT02465060 ​Molecular Analysis for Therapy Choice (MATCH) ​Bradley Haverkos​
NCT02074839​​ ​A Phase 1 study to assess the safety and tolerability of treatment with AG-120 in patients with IDH1 mutations (includes MDS and peripheral T-cell lymphoma subtypes with IDH1 mutation) ​ ​Rachel Freeby, 720-848-0736
​​​13

 Acute Lymphoblastic Leukemia (non transplant)

No current trials recruiting​​
​​​​1

 Acute Myeloid Leukemia (non-transplant)

 
ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
​NCT02848248 ​A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML). Kayla Fischer, 720-848-0736

NCT02335814​​

​Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia. Natalie Monson, 720-848-2199
​NCT02203773 ​A Phase​ 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. ​Rachel Freeby, 720-848-0736​​

NCT02074839​​​​

​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation. Rachel Freeby, 720-848-0736​
NCT02577406​ A phase 2, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation.
Rachel Freeby, 720-848-0736​​

NCT02472145

​A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy Shirstine Rahkola, 720-848-1776​
NCT02670044 ​A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy ​Shirstine Rahkola, 720-848-1776​​
​NCT02632708​ ​A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation ​Tricia Feddick, 720-848-8034​

​​​​​​​​​​​​​​​​​​​​10

 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01886859 A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ​Nicole Adler, 720-848-0678

NCT02475681

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

Natalie Monson, 720-848-2199

​​​​​2

 Hodgkin Lymphoma (non transplant)

No current trials recruiting​​3

 Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT02074839 ​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation.

Rachel Freeby, 720-848-0736​

NCT02706899​ ​​​A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) Megan McClain, 720-848-3773​​​​

​​​4

 Myeloma (non transplant)

ClinicalTrials.gov Identifier Study Title Study Coordinator
​​NCT02755597​ A phase 3, multicenter, randomized, double blind, study of Bortezomib and Dexamethasone in combination with either Venetoclax or placebo in subjects with relapsed or refractory multiple myeloma who are sensitive or naïve to proteasome inhibitors
Megan McClain, 720-848-3773​​​​
NCT02576977 ​ ​A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183) Kelsey Moore, 720-848-8089​​​​
​​​​​​​5

 OLD-Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​​6

 OLD-Non Hodgkin Lymphoma: Mantle Cell (non transplant)

​No current trials recruiting7

 OLD-Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
​NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. ​Natalie Monson, 720-848-2199​
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
NCT02567656​  ​A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma ​Kelsey Moore, 720-848-8089​​
​​​​​​8

 Transplant

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator​
​NCT01841333 ​A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ​​Natalie Monson, 720-848-2199​
​​​​​​9